Parathyroid Hormone Related Protein and Hypercalcaemia in Breast Cancer

Overview

Journal BMJ

Specialty General Medicine

Date 1991 Dec 14

PMID 1782489

Citations 18

Authors

N J Bundred

W A Ratcliffe

R A Walker

S Coley

J M Morrison

J G Ratcliffe

Affiliations

Soon will be listed here.

Abstract

Objective: To see whether parathyroid hormone related protein has a humoral role in breast cancer.

Design: Plasma concentrations and tumour expression of parathyroid hormone related protein were determined (by two site immunoradiometric assay and immunohistochemistry respectively) in women with breast cancer and related to the presence of bone metastases and serum calcium concentrations.

Subjects: Plasma concentrations of parathyroid hormone related protein were measured in 57 women with early breast cancer without apparent bone metastases, 28 women with bone metastases, and 13 women with bone metastases and hypercalcaemia. Tissue positivity for parathyroid hormone related protein was determined retrospectively in 106 primary breast tumours from women without apparent bone metastases and 72 tumours from women with bone metastases, 25 of whom subsequently developed hypercalcaemia.

Results: Plasma parathyroid hormone related protein concentrations were detectable (greater than 0.23 pmol/l) in 12 (92%) of the 13 hypercalcaemic patients with bone metastases compared with 10 (36%) of the 28 normocalcaemic patients with bone metastases and five (9%) of the 57 normocalcaemic patients without bone metastases. Parathyroid hormone related protein concentrations were significantly higher in hypercalcaemic than normocalcaemic patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in 22 (88%) of the 25 primary breast cancers from patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in 22 (88%) of the 25 primary breast cancers from patients with bone metastases who later developed hypercalcaemia compared with 25 (53%) of the 47 from women in this group who remained normocalcaemic and 55 (52%) of the 106 early breast cancers from women without known metastases.

Conclusion: Tumour derived parathyroid hormone related protein may have an important humoral role in hypercalcaemia associated with metastatic breast cancer.

Citing Articles

A Retrospective Study of Clinical and Histopathological Features of 81 Cases of Canine Apocrine Gland Adenocarcinoma of the Anal Sac: Independent Clinical and Histopathological Risk Factors Associated with Outcome.

Wong H, Byrne S, Rasotto R, Drees R, Taylor A, Priestnall S Animals (Basel). 2021; 11(11).

PMID: 34828058 PMC: 8614406. DOI: 10.3390/ani11113327.

Animal Models of Cancer-Associated Hypercalcemia.

Kohart N, Elshafae S, Breitbach J, Rosol T Vet Sci. 2017; 4(2).

PMID: 29056680 PMC: 5606604. DOI: 10.3390/vetsci4020021.

Implications of Hypoxia in Breast Cancer Metastasis to Bone.

Gilkes D Int J Mol Sci. 2016; 17(10).

PMID: 27706047 PMC: 5085702. DOI: 10.3390/ijms17101669.

Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.

Furugaki K, Moriya Y, Iwai T, Yorozu K, Yanagisawa M, Kondoh K Clin Exp Metastasis. 2011; 28(7):649-59.

PMID: 21688034 PMC: 3198194. DOI: 10.1007/s10585-011-9398-4.

Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.

Kozlow W, Guise T J Mammary Gland Biol Neoplasia. 2005; 10(2):169-80.

PMID: 16025223 DOI: 10.1007/s10911-005-5399-8.

References

Burtis W, BRADY T, Orloff J, Ersbak J, Warrell Jr R, Olson B . Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med. 1990; 322(16):1106-12. DOI: 10.1056/NEJM199004193221603. View

Percival R, Yates A, Gray R, Galloway J, Rogers K, NEAL F . Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed). 1985; 291(6498):776-9. PMC: 1417171. DOI: 10.1136/bmj.291.6498.776. View

Mundy G, Ibbotson K, Dsouza S, Simpson E, Jacobs J, Martin T . The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med. 1984; 310(26):1718-27. DOI: 10.1056/NEJM198406283102607. View

Legha S, Powell K, Buzdar A, Blumenschein G . Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981; 47(12):2803-6. DOI: 10.1002/1097-0142(19810615)47:12<2803::aid-cncr2820471208>3.0.co;2-a. View

Ralston S, Danks J, Hayman J, Fraser W, Stewart C, Martin T . Parathyroid hormone-related protein of malignancy: immunohistochemical and biochemical studies in normocalcaemic and hypercalcaemic patients with cancer. J Clin Pathol. 1991; 44(6):472-6. PMC: 496827. DOI: 10.1136/jcp.44.6.472. View

Ratcliffe W, Norbury S, Heath D, Ratcliffe J . Development and validation of an immunoradiometric assay of parathyrin-related protein in unextracted plasma. Clin Chem. 1991; 37(5):678-85. View

Powell G, Southby J, Danks J, Stillwell R, Hayman J, Henderson M . Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 1991; 51(11):3059-61. View

Kramer S, Reynolds Jr F, Castillo M, Valenzuela D, Thorikay M, Sorvillo J . Immunological identification and distribution of parathyroid hormone-like protein polypeptides in normal and malignant tissues. Endocrinology. 1991; 128(4):1927-37. DOI: 10.1210/endo-128-4-1927. View

Gallacher S, Fraser W, Patel U, Logue F, Soukop M, Boyle I . Breast cancer-associated hypercalcaemia: a reassessment of renal calcium and phosphate handling. Ann Clin Biochem. 1990; 27 ( Pt 6):551-6. DOI: 10.1177/000456329002700605. View

10.

Southby J, Kissin M, Danks J, Hayman J, Moseley J, Henderson M . Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res. 1990; 50(23):7710-6. View

11.

Martin T . Properties of parathyroid hormone-related protein and its role in malignant hypercalcaemia. Q J Med. 1990; 76(280):771-86. View

12.

Coleman R, Fogelman I, Rubens R . Hypercalcaemia and breast cancer--an increased humoral component in patients with liver metastases. Eur J Surg Oncol. 1988; 14(5):423-8. View

13.

Isales C, Carcangiu M, Stewart A . Hypercalcemia in breast cancer. Reassessment of the mechanism. Am J Med. 1987; 82(6):1143-7. DOI: 10.1016/0002-9343(87)90216-6. View

14.

Mundy G . Hypercalcemia of malignancy revisited. J Clin Invest. 1988; 82(1):1-6. PMC: 303467. DOI: 10.1172/JCI113555. View

15.

Martin T, Suva L . Parathyroid hormone-related protein in hypercalcaemia of malignancy. Clin Endocrinol (Oxf). 1989; 31(5):631-47. DOI: 10.1111/j.1365-2265.1989.tb01288.x. View

16.

Budayr A, Nissenson R, Klein R, Pun K, Clark O, Diep D . Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med. 1989; 111(10):807-12. DOI: 10.7326/0003-4819-111-10-807. View

17.

Danks J, Ebeling P, Hayman J, Chou S, Moseley J, Dunlop J . Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res. 1989; 4(2):273-8. DOI: 10.1002/jbmr.5650040221. View

18.

BIJVOET O, Cleton F, Hermans J, Kroon H, Harinck H, Vermey P . Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987; 2(8566):983-5. DOI: 10.1016/s0140-6736(87)92555-4. View

19.

Sato K, Fujii Y, Kasono K, Tsushima T, SHIZUME K . Production of interleukin-1 alpha and a parathyroid hormone-like factor by a squamous cell carcinoma of the esophagus (EC-GI) derived from a patient with hypercalcemia. J Clin Endocrinol Metab. 1988; 67(3):592-601. DOI: 10.1210/jcem-67-3-592. View

20.

Suva L, Winslow G, Wettenhall R, HAMMONDS R, Moseley J, Rodda C . A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 1987; 237(4817):893-6. DOI: 10.1126/science.3616618. View